Contact Us

BUSINESS NEWS

SiPH Collaborates with IBM to Enhance Pathology Information System with Computational Advances and AI to Support Patients in Thailand and ASEAN

Nov 20, 2024

BANGKOK,Nov. 19,2024-- Siriraj Piyamaharajkarun Hospital (SiPH),operating under Faculty of Medicine Siriraj Hospital,today announced a successful transformation of its Pathology Information System (P

Wealth Broker: The One-stop Wealth Management Platform Trusted by Investors

Nov 20, 2024

SINGAPORE,Nov. 19,2024-- Wealth Broker\'s brokerage app has undergone a major technical upgrade in the third quarter of this year,enhancing compliance and user service experience.

Pop Culture Announces Improvement in Overall Operations During the Fiscal Year Ended June 30, 2024

Nov 20, 2024

XIAMEN,China,Nov. 19,2024-- In the fiscal year ended June 30,2024,POP CULTURE GROUP CO.,LTD. ("Pop Culture," or the "Company," Nasdaq: CPOP) continued to focus on its three busines

Xinhua Silk Road: E. China's fishing village recognized as Best Tourism Village by UN Tourism

Nov 20, 2024

BEIJING,Nov. 19,2024-- Yandunjiao Village in east China\'s Shandong Province and six other Chinese villages were announced as Best Tourism Villages by the United Nations World Tourism Organization (UN

2024 Access to Medicine Index finds that pharma companies are missing opportunities to reach more patients in low- and middle-income countries

Nov 20, 2024

AMSTERDAM,Nov. 19,2024-- The 2024 Access to Medicine Index finds that pharmaceutical companies are not fully leveraging their potential to expand access in underserved regions. While the Foundation\'s

Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA

Nov 20, 2024

48-week end-of-treatment data from theongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-IFNα

1 ... 99 100 101 102 103 104 105 ... 235